Please assess the completion status of the following clinical trial:

Trial Title: Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically and clinically confirmed multiple myeloma~  * Relapsed and/or refractory after chemotherapy or transplantation~    * Patients with prior allogeneic transplantation must not have evidence of active graft-vs-host disease requiring immune suppression~* Measurable disease defined by quantitative immune globulin levels in serum and/or urine and bone marrow plasmacytosis~  * Patients with nonsecretory disease are eligible provided at least 1 plasmacytoma lesion is accurately measurable by MRI or CT scan~* No known CNS involvement~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2 OR~* Karnofsky 60-100%~Life expectancy~* More than 3 months~Hematopoietic~* See Disease Characteristics~* Absolute neutrophil count at least 1,000/mm\^3\*~* Platelet count at least 50,000/mm\^3\* NOTE: \*Unless secondary to bone marrow plasmacytosis (more than 80% involvement)~Hepatic~* Bilirubin less than 2 times normal~* AST/ALT no greater than 3 times upper limit of normal~Renal~* Creatinine no greater than 2 mg/dL~Cardiovascular~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Other~* Seizures allowed if under adequate control~* No severe skin reactions from prior thalidomide~* No prior allergic reactions attributed to agents used in this study~* No sensory or motor neuropathy grade II or greater~* No other uncontrolled concurrent illness that would preclude study therapy~* No ongoing or active infection~* No psychiatric illness or social situations that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 effective methods of contraception for 1 month before, during, and for 1 month after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* See Chemotherapy~* At least 6 weeks since prior thalidomide~Chemotherapy~* See Disease Characteristics~* No more than 4 prior chemotherapy regimens, including autologous and/or allogeneic stem cell transplantation regimens~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered~Endocrine therapy~* Concurrent continuous steroids allowed for chronic treatment of disorders other than myeloma~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No prior oblimersen~* No other concurrent anticancer therapies or investigational agents~* No concurrent combination antiretroviral therapy for HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).